Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.85 NOK | +0.64% |
|
-9.04% | -93.61% |
06-11 | Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma | CI |
05-07 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-93.61% | 25.46M | |
+34.14% | 51.51B | |
-6.54% | 39.03B | |
+34.92% | 38.91B | |
-12.11% | 26.68B | |
+12.62% | 26.13B | |
-13.43% | 19.91B | |
+43.73% | 13.71B | |
+31.81% | 12.38B | |
-4.54% | 11.74B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Ultimovacs Finalizes Patient Recruitment for Supplementary Study of Cancer Vaccine